Document Detail

Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans.
MedLine Citation:
PMID:  9920148     Owner:  NLM     Status:  MEDLINE    
To elucidate the etiology of valproic acid-induced carnitine deficiency, we tested the hypothesis that long-term valproic acid administration decreases the rate of carnitine reabsorption. Thirteen healthy men participated in a 34-day protocol in which carnitine clearance was measured before and after 28 days of valproic acid administration. During valproic acid administration (days 6 to 33), plasma free and total carnitine concentrations decreased (18% and 12%, respectively, P<.05) by 16 days, but returned to pretreatment concentrations by 28 days. From day 14 to day 30, the rate of free carnitine excretion was 50% lower than at baseline (day 4, P<.05). Free and total carnitine clearance, indexed to the glomerular filtration rate, was lower after valproic acid administration (P<.01). Contrary to our hypothesis, after 28 days of valproic acid administration, the rate of carnitine reabsorption was enhanced independent of the glomerular filtration rate and filtered load. Changes in the plasma concentration, rate of excretion, and clearance were specific for carnitine and were not generalized in magnitude or direction to the other amino acids. We conclude that the kidney adapts to conserve carnitine during valproic acid administration and therefore does not cause valproic acid-induced carnitine depletion in adults.
D D Stadler; J F Bale; C A Chenard; C J Rebouche
Related Documents :
24962508 - Experimental and clinical efficacy of two hyaluronic acid-based compounds of different ...
24577928 - Development and in vitro evaluation of a transdermal hydrogel patch for ferulic acid.
23450038 - Anaphylaxis to topically applied sodium fusidate.
23377328 - Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing ...
10725558 - Characterisation of acyl-acp desaturases from macadamia integrifolia maiden & betche an...
2096588 - The rationale for using ursodeoxycholic acid in chronic liver disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  48     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  1999 Jan 
Date Detail:
Created Date:  1999-02-04     Completed Date:  1999-02-04     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  74-9     Citation Subset:  IM    
Department of Pediatrics, and General Clinical Research Center, University of Iowa College of Medicine, Iowa City, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / adverse effects*
Carnitine / deficiency,  metabolism*
Kidney / metabolism
Valproic Acid / adverse effects*
Grant Support
Reg. No./Substance:
0/Anticonvulsants; 541-15-1/Carnitine; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercho...
Next Document:  Peripheral tissue glucose uptake is not reduced after an oral glucose load in Southern Italian subje...